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Brain is the most energetically demanding organ of the body, and is thus vulnerable
to even modest decline in ATP generation. Multiple neurodegenerative diseases are
associated with decline in mitochondrial function, e.g., Alzheimer’s, Parkinson’s, multiple
sclerosis and multiple neuropathies. Genetic variances in the mitochondrial genome
can modify bioenergetic and respiratory phenotypes, at both the cellular and system
biology levels. Mitochondrial haplotype can be a key driver of mitochondrial efficiency.
Herein, we focus on the association between mitochondrial haplotype and risk of late
onset Alzheimer’s disease (LOAD). Evidence for the association of mitochondrial genetic
variances/haplotypes and the risk of developing LOAD are explored and discussed.
Further, we provide a conceptual framework that suggests an interaction between
mitochondrial haplotypes and two demonstrated risk factors for Alzheimer’s disease
(AD), apolipoprotein E (APOE) genotype and chromosomal sex. We posit herein that
mitochondrial haplotype, and hence respiratory capacity, plays a key role in determining
risk of LOAD and other age-associated neurodegenerative diseases. Further, therapeutic
design and targeting that involve mitochondrial haplotype would advance precision
medicine for AD and other age related neurodegenerative diseases.
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INTRODUCTION
A central role of mitochondria in age-related metabolic and neurodegenerative diseases has
long been proposed, and an association between mitochondrial dysfunction and Alzheimer’s
disease has been long proposed across multiple investigative strategies from analysis of
human tissue to cell model systems (Beal, 1996; Gibson et al., 2000; Trimmer et al., 2000;
Swerdlow and Khan, 2004; Bubber et al., 2005; Wallace, 2005; Lin and Beal, 2006; Brinton,
2008, 2009; Khusnutdinova et al., 2008; Simpkins et al., 2008; Coskun et al., 2012; Brinton
et al., 2015). The ‘‘mitochondrial cascade hypothesis’’, originally proposed by Swerdlow
and Khan (2004) as an explanation for late onset Alzheimer’s disease (LOAD), proposed
that inherited mitochondrial genetic variations and mutations accumulated from aging
should occupy the apex of the disease cascade. Briefly, this hypothesis maintained that
mitochondrial genetic variations and mutations lead to deficient electron transport chain
function, resulting in less ATP production, increased free radical production, disrupted
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FIGURE 1 | Modified mitochondrial cascade of late-onset Alzheimer’s disease (LOAD). Inherited mitochondrial genetic variations and accumulated
mutations during aging lead to deficiency in mitochondrial functions, initiating a cascade of events including reduced ATP production, increased free radical formation
and ER stress, disrupted mitochondrial associated membrane (MAM) function and mitochondrial dynamics, as well as amyloid beta plaque and tau tangle formation,
which result in further damages of mitochondria and ultimately leads to apoptosis and neurodegeneration, such as LOAD.
calcium homeostasis, beta amyloid production and plaque
deposition, and tau phosphorylation and tangle formation.
These results in turn lead to further damage of mitochondrial
DNA, proteins, and lipids, and the opening of mitochondrial
permeability transition pore, which ultimately leads to cell
death and neurodegeneration (see Figure 1). Recent studies
also indicated disrupted crosstalk between mitochondria and
endoplasmic reticulum (ER) via mitochondrial associated
membrane (MAM), as well as abnormal mitochondrial dynamics
in the etiology of Alzheimer’s disease (AD; Trimmer et al., 2000;
Baloyannis et al., 2004; Paillusson et al., 2013; Burté et al., 2015;
Zhang et al., 2016; see Figure 1).
Here we review the link between mitochondrial dysfunction
and the risk of AD, the contribution of mitochondrial genetic
variances to the risk, and how the risk is modulated by other
factors, such as apolipoprotein E (APOE) genotype and sex
differences.
MITOCHONDRIAL GENOME AND
HAPLOTYPES
Unlike many other organelles, mitochondria have their own
genome. The human mitochondrial genome is a circular set
of 16,569 base pairs encoding 37 genes. Thirteen of these
genes encode protein subunits required for four of the five
electron transport chain complexes: complex I (NADH
ubiquinone oxidoreductase), complex III (cytochrome bc1
complex), complex IV (cytochrome c oxidase), and complex
V (ATP synthase); two encode rRNAs for mitochondrial
ribosomes (12S and 16S), and 22 encode tRNAs (see
Figure 2).
Mitochondrial retention of their own genome throughout
evolution solves two cell biology problems. First, the 13
electron transport subunits coded by mitochondrial DNA solves
the problem that if they were generated by nuclear DNA,
they would not cross the inner mitochondria membrane due
to their high hydrophobicity (Popot and de Vitry, 1990).
Second, the eukaryotic mitochondrial genome is transcribed
and translated quite differently than the nuclear genome
(Mercer et al., 2011). The genetic system of the mitochondria
is transcribed as precursor polycistronic transcripts that are
subsequently cleaved to generate mRNAs, tRNAs and rRNAs
(Mercer et al., 2011). The mRNAs devoted to generating the
13 catalytic subunits required for oxidative phosphorylation are
further translated using several non-universal codons unique
to the mitochondrial translation machinery (Watanabe, 2010;
Watanabe and Yokobori, 2011).
Like nuclear DNA, mitochondrial DNA undergoes mutation,
though at a much higher rate (Miyata et al., 1982; Wallace
et al., 1987), likely due to higher replication rate, a more
Frontiers in Aging Neuroscience | www.frontiersin.org 2 October 2016 | Volume 8 | Article 232
Wang and Brinton Mitochondria, APOE, Sex, and LOAD
FIGURE 2 | Human mitochondrial DNA. Orange indicates protein-encoding genes (13), purple indicates mitochondrial rRNAs (2), blue indicates tRNAs (22), and
gray indicates the D-loop. OH: heavy strand origin, OL: light strand origin, HSP1: major heavy strand promoter, HSP2: minor heavy strand promoter, LSP, light strand
promoter.
mutagenic environment, and less efficient DNA repair
(Xu et al., 2012). Unlike the nucleus, the mitochondrial
DNA repair mechanism is largely limited to base excision
repair. Mismatch as a result of either recombination
or repair can lead to single nucleotide polymorphisms
(SNPs).
Clusters of specific SNPs in the mitochondrial genome
define mitochondrial haplogroups that reflect maternal lineage
(Giles et al., 1980; Torroni et al., 1992). For example, the four
lineages specific for sub-Saharan Africa are L0, L1, L2 and L3,
and haplogroups A, B, C, D, G and F are common in Asia
(Stewart and Chinnery, 2015). The major haplogroups within
descendants of European ancestry are haplogroups H, I, J, K,
M, T, U, V, W and X (Torroni et al., 1996). These haplogroups
can be further classified into subhaplogroups or clustered
together into superhaplogroups, such as superhaplogroup HV,
JT, UK.
MITOCHONDRIAL DYSFUNCTION AND
INCREASED RISK OF ALZHEIMER’S
DISEASE
AD is a systemic disease with multiple etiologies (Morris et al.,
2014). Early evidence linking mitochondrial dysfunction to AD
dates back to a 1987 study by Sims et al. (1987), who found a
reduced rate of oxygen uptake in the presence and absence of
ADP in frontal neocortex of postmortem confirmed AD cases,
indicating potential mitochondrial uncoupling in AD patients
(Sims et al., 1987).
More direct evidence for the association between
mitochondrial dysfunction and AD came later from studies
on the activity of electron transport chain enzymes in AD
patients and post mortem AD brain tissues. In the early
1990’s, reduced cytochrome c oxidase (complex IV) activity
was observed in both platelets and postmortem AD brain
Frontiers in Aging Neuroscience | www.frontiersin.org 3 October 2016 | Volume 8 | Article 232
Wang and Brinton Mitochondria, APOE, Sex, and LOAD
(Parker et al., 1990, 1994). The reduction of cytochrome c
activity in AD brain was later refined to the temporal cortex
and hippocampus (Maurer et al., 2000). Supporting these
findings, reduced mRNA levels of cytochrome c oxidase
subunit 1 and 3 were observed in AD mid temporal gyrus
and cytochrome c oxidase subunit 2 in AD hippocampus
(Chandrasekaran et al., 1994; Aksenov et al., 1999). Furthermore,
in both AD temporal and parietal cortices, protein levels of
cytochrome c oxidase subunits were reduced, especially those
encoded by mitochondria DNA (Kish et al., 1999). Although
no reduction of cytochrome c oxidase content was observed
in platelets of AD patients, cytoplasmic hybrids (cybrids)
containing exogenous mitochondria extracted from platelets
of AD patients showed less cytochrome c oxidase activity
compared to cybrids harboring mitochondria from age-matched
controls (Davis et al., 1997; Sheehan et al., 1997; Cardoso
et al., 2004). Alternations in gene expression, protein level,
and activity of other electron transport chain complexes have
also been reported in AD tissues, though the evidence was less
compelling and sometimes contradicted (Schagger and Ohm,
1995; Chandrasekaran et al., 1997; Aksenov et al., 1999; Kim
et al., 2000; Bosetti et al., 2002; Bubber et al., 2005; Valla et al.,
2006).
Upstream to electron transport chain, impairment of the
tricarboxylic acid (TCA) cycle enzymes was observed in
AD brain. Autopsy-confirmed AD brain had significantly
reduced activity in pyruvate dehydrogenase complex, isocitrate
dehydrogenase, and α-ketoglutarate dehydrogenase complex,
whereas the activity of succinate dehydrogenase and malate
dehydrogenase were increased (Bubber et al., 2005). The
severity of enzyme activity impairment was also correlated
with the clinical severity of Alzheimer’s pathology (Bubber
et al., 2005). Decreased mitochondrial respiratory capacity was
consistent with the higher level of lactate and lower key
substrates for TCA cycle in cerebrospinal fluid and blood in
AD patients (Redjems-Bennani et al., 1998; Mancuso et al.,
2003).
Consistent with deficits inmitochondrial respiratory capacity,
AD brain had elevated levels of peroxidation products in
the frontal cortex, as well as decreased levels of superoxide
dismutase, a radical defensive enzyme, in the frontal cortex,
hippocampus, and cerebellum (Richardson, 1993). Increased
oxidative stress is consistent with free radical damage of
mitochondrial components and loss of mitochondrial membrane
potential as observed in cybrids harboring mitochondria
with AD origin (Cassarino et al., 1998; Trimmer et al.,
2000).
Besides altered bioenergetic capacity, the crosstalk between
mitochondria and the ER via MAM, which regulates many key
functions of mitochondria, such as calcium uptake, phospholipid
exchange, intracellular trafficking, ER stress and mitochondrial
biogenesis, was also disrupted in AD (Paillusson et al., 2013;
Burté et al., 2015).
Beyond changes in mitochondrial function, distribution and
morphology of mitochondria were also different in AD patients.
Neurons from AD brain harbored mitochondria of smaller sizes
and disrupted mitochondrial cristae morphology, and cybrids
created using mitochondria from sporadic AD patients also
showed swollen mitochondria and less cristae (Trimmer et al.,
2000; Baloyannis et al., 2004). The fission and fusion cycle of
mitochondria also seemed disrupted in the hippocampus of
AD brain (Zhang et al., 2016). The number of mitochondria
was also significantly reduced, likely as a result of increased
mitochondria degradation, turnover and autophagy (Hirai et al.,
2001).
AD has a pattern of maternal inheritance, where inheritance
of AD frommothers are more frequent than from fathers (Duara
et al., 1993). The observation of maternal pattern of Alzheimer’s
inheritance has been replicated over many decades by multiple
groups, and has been linked to deficits in mitochondrial
respiration and glucose metabolism apparently early in the aging
process (Edland et al., 1996; Mosconi et al., 2011; Liu et al.,
2013). In cognitively normal individuals, those with a maternal
history of LOAD showed decline in platelet cytochrome c oxidase
activity, compared to those with a paternal or no family history
of the disease (Edland et al., 1996; Mosconi et al., 2011). In
this same cohort, Mosconi et al. (2011) observed significantly
lower brain glucose metabolism in persons with a maternal
history of Alzheimer’s relative to those with a paternal or no
family history of the disease. These data coupled with maternal
inheritance of the mitochondrial genome strongly support a
role for mitochondrial genetic variances in the etiology of the
disease.
MITOCHONDRIAL HAPLOTYPE IS
ASSOCIATED WITH DIFFERENT
RESPIRATORY, METABOLIC AND
BIOENERGETIC PHENOTYPES
Mitochondrial genetic background can also affect metabolism
and bioenergetic function. Resting metabolic rate (RMR)
and total energy expenditure (TEE) were measured in 294
participants in the health, aging and body composition study
(Health ABC; Tranah et al., 2011), including participants of
cluster L, which contains common African haplogroups, and
cluster N, which contains common European haplogroups
(Tranah et al., 2011). Compared to N, cluster L had significantly
lower RMR and TEE. Specifically, haplogroups L0, L2 and
L3 had significantly lower RMR than haplogroup H and
superhaplogroups UK and JT; haplogroup L3 had significantly
lower TEE than haplogroup H and superhaplogroups UK
and JT; haplogroup L2 had significantly lower TEE than
haplogroup H and superhaplogroup JT (Tranah et al.,
2011; see Table 1). In a cohort of healthy Spanish males,
haplogroup J participants had significantly lower maximum
oxygen consumption (VO2max) than non-J participants
(Marcuello et al., 2009). This difference was later confirmed
in an independent cohort of healthy Spanish males, where
haplogroup H was determined to be the driving force
for the difference (Martínez-Redondo et al., 2010; see
Table 1).
The underlying cellular mechanism of the observed
differences across different mitochondrial haplogroups was
Frontiers in Aging Neuroscience | www.frontiersin.org 4 October 2016 | Volume 8 | Article 232
Wang and Brinton Mitochondria, APOE, Sex, and LOAD
TABLE 1 | Mitochondrial haplogroups/superhaplogroups differentially
associated with respiratory phenotypes.
Relatively high Relatively low Reference
RMR H, UK, JT L2, L3, L3 Tranah et al. (2011)
TEE H, UK, JT L0, L2 Tranah et al. (2011)
VO2max H J Marcuello et al. (2009) and
Martínez-Redondo et al. (2010)
Individuals of haplogroup/superhaplogroups H, UK and JT had higher rest
metabolism rate (RMR), total energy differences (TEE) and/or VO2max compared
to individuals of cluster L and haplogroup J.
primarily elucidated using trans-mitochondrial cytoplasmic
hybrids, or cybrids, which controlled for the nuclear genetic
background to reveal mitochondrial variances. An early
cybrids study using cultured A539 human lung carcinoma
cells harboring either mitochondria of haplogroup H or T
failed to identify any differences in bioenergetics function
(Amo et al., 2008). However, differences in bioenergetics
and mitochondrial function were identified in multiple later
studies using different cell lines and mitochondrial haplogroups.
Cybrids constructed from osteosarcoma 143B rho0 cells and
platelets from healthy Spanish donors of either haplogroup
H or superhaplogroup UK were investigated for mtDNA
content (Gómez-Durán et al., 2010). Cybrids harboring UK
superhaplogroup were found to have lower mtDNA content,
lower mt-rRNA level, reduced protein synthesis, and decreased
cytochrome c oxidase amount (Gómez-Durán et al., 2010).
UK cybrids also had lower mitochondrial inner membrane
potential and higher mitochondrial uncoupling, indicating
potentially lower respiratory capacity and reduced ATP
production (Gómez-Durán et al., 2010). Similar results were
obtained in a later study in middle-age Caucasian males, where
OXPHOS capacity normalized to citrate synthase content was
found to be reduced by 24% in subjects with haplogroup U
background comparing to those with haplogroup H background
(Larsen et al., 2014). In 2013, cybrids constructed from human
retinal epithelial cell line ARPE-19 and either haplogroup
H or J mitochondria showed reduced ATP production and
glycolysis in J cybrids (Kenney et al., 2013). In accordance
with the observed reduction in mitochondrial respiration,
J cybrids also showed lower ROS production (Kenney et al.,
2013). Haplogroup J cybrids with chondrocyte nuclear genetic
background also demonstrated lower NO levels than non-J
cybrids (Fernández-Moreno et al., 2011). Similarly, major
Asian mitochondrial haplogroups are also differentially
associated with bioenergetic function (Lin et al., 2012).
These associations identified in the human are also evident
in animal models ranging from Drosophila to mice such that
different mitochondrial genetic background is associated with
differences in respiratory and metabolic phenotypes, electron
transport chain enzyme activities and mitochondrial functions
(Pichaud et al., 2012; Scheffler et al., 2012; Latorre-Pellicer et al.,
2016).
Although different nuclear genetic background employed in
the above studies make it difficult to compare the results across
studies, this growing body of evidence supports mitochondrial
genetic variance/haplotype as a key factor in the observed
differences in bioenergetics and metabolism.
MITOCHONDRIAL GENETIC
VARIANCES/HAPLOTYPES AND
HAPLOGROUPS AND THE RISK OF
ALZHEIMER’S DISEASE
In an early effort to assess the contribution of mitochondrial
DNA variances to pathologies of neurodegenerative diseases,
researchers identified a non-synonymous SNP in tRNAGln,
mt4336C, that had an increased frequency in a Caucasian
cohort of late onset Alzheimer’s and Parkinson disease patients
(Shoffner et al., 1993). The contribution of mt4336C was later
confirmed in a different North American Caucasian cohort
of AD patients (Hutchin and Cortopassi, 1995). Individuals
harboring the mt4336C SNP also tended to harbor the mt16304C
SNP, and had a more closely related D-loop sequence, which
could be traced back to a single phylogenetic node (Shoffner
et al., 1993; Hutchin and Cortopassi, 1995). However, two
other studies did not confirm either mt4336C or mt16304C
as a risk factor for developing AD in similar populations,
when blood samples and leukocytes from clinically diagnosed
patients were used instead of histopathologically confirmed
postmortem AD brain tissues (Wragg et al., 1995; Zsurka
et al., 1998). Today, mt16304C is known as a defining SNP
for subhaplogroup H5, and mt4336C a defining SNP for
subhaplogroup H5a. The above studies constituted the earliest
debate over whether mitochondrial genetic variances can modify
the risk of developing AD.
In fact, haplogroup H and superhaplogroup HV, which
contains haplogroup H and its subhaplogroups, have been the
most reported haplogroup in association with increased risk
of developing AD (Chinnery et al., 2000; Edland et al., 2002;
van der Walt et al., 2004, 2005; Elson et al., 2006; Fesahat
et al., 2007; Mancuso et al., 2007; Maruszak et al., 2009, 2011;
Santoro et al., 2010; Coto et al., 2011; Ridge et al., 2012;
Fachal et al., 2015; see Table 2). A study based on 30 Iranian
late onset Alzheimer’s patients and 100 controls found that
haplogroup H was significantly more abundant in the disease
group (Fesahat et al., 2007; see Table 2). In a Spanish-Caucasian
group, haplogroup H and its defining SNP mt7028C were
enriched in LOAD patients compared to controls (Coto et al.,
2011; see Table 2). In a large Caucasian cohort containing 422
late-onset AD patients and 318 neurologically healthy controls,
researchers found that superhaplogroup HV, which contains
haplogroup H, had significantly higher presence in LOAD than
in control (Maruszak et al., 2011; see Table 2). Finally, a
meta-analysis pooling data from five previous studies (some
studies including early-onset AD patients) also confirmed the
association between haplogroup H and superhaplogroup HV
and the risk of developing AD (Maruszak et al., 2011; see
Table 2).
When mitochondrial DNA was sequenced in greater depth,
subhaplogroup H5 was significantly associated with AD
compared to haplogroup H of central-northern Italians, (Santoro
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TABLE 2 | Observed effects of mitochondrial superhaplogroup HV and haplogroup H on risk of Alzheimer’s disease (AD).
Haplogroups Observations Reference
HV Increased risk, especially in females Maruszak et al. (2011)
No effect Elson et al. (2006), Maruszak et al. (2009) and Fachal et al. (2015)
H Increased risk Fesahat et al. (2007), Maruszak et al. (2009, 2011) and Coto et al. (2011)
Defining SNP mt7028C increased risk Coto et al. (2011)
Defining SNP mt7028C increased risk in females only van der Walt et al. (2004)
H5 increased risk, especially in females Santoro et al. (2010)
H5 and APOE4 synergistically increased risk Maruszak et al. (2011)
H5a defining SNP mt4336C increased risk in APOE4 carriers Edland et al. (2002)
H6a1a and H6a1b decreased risk Ridge et al. (2012)
No effect Chinnery et al. (2000), van der Walt et al. (2005), Mancuso et al. (2007) and
Fachal et al. (2015)
Effects of haplogroup H defining single nucleotide polymorphisms (SNPs) and its subhaplogroups are listed under haplogroup H.
et al., 2010; see Table 2). However, from the Cache county
study on aging and memory in Utah residents, subhaplogroups
H6a1a and H6a1b were found to be protective against AD
(Ridge et al., 2012; see Table 2). While the protective role
of subhaplogroups H6a1a and H6a1b seems contradictory to
the overall risk of haplogroup H, the data predict that the
observed risks within haplogroup H may be driven by its sub-
haplogroups withH5 increases risk of LOADwhereas H6 reduces
risk.
The second most studied superhaplogroup is UK, and its
member haplogroups U and K, including their subhaplogroups
(While haplogroup K is currently recognized as a branch
of haplogroup U, early studies classified haplogroups U
and K as two parallel haplogroups under superhaplogroup
UK. For consistency of referring to previous studies, we
will use the earlier classification system throughout this
review article; see Table 3). In a Utah based ADNI cohort,
superhaplogroup UK was identified as a risk factor for AD
(Lakatos et al., 2010; see Table 3). These findings are in
contrast to an earlier study conducted in a Poland-based
Caucasian population, where no effect of superhaplogroup
UK was observed (Maruszak et al., 2009; see Table 3). The
disparity may be explained by differences in the distribution
of specific subhaplogroups or SNPs in the studied populations.
Specifically, while each of the three defining SNPs for haplogroup
U (mt11467G, mt12308G and mt12372A) has been identified
as a risk factor for AD (Lakatos et al., 2010), subhaplogroup
U5a1 and SNP mt16224C, a haplogroup K defining SNP,
were shown to be protective (Maruszak et al., 2011; see
Table 3).
Another common European haplogroup studied for its
association with AD is haplogroup T, where one study in
French-Canadians found that the frequency of SNPs mt709A
and mt15928A, both defining SNPs for haplogroup T, were
three times higher in controls than in AD patients, suggesting
a protective role of haplogroup T (Chagnon et al., 1999; see
Table 4). However, the Health, Aging, and Body Composition
(Health ABC) study found that haplogroup T had increased risk
for dementia when compared to haplogroup H (Tranah et al.,
2012). The Health ABC study also found that haplogroup J,
also under superhaplogroup JT, was associated with significant
decline in cognitive function compared to haplogroupH (Tranah
et al., 2012).
In addition to major European haplogroups, several African
and Asian haplogroups have also been reported to be associated
with the AD or risk of dementia (see Table 5). For example,
TABLE 3 | Observed effects of mitochondrial superhaplogroup KU and haplogroups K and U on risk of AD.
Haplogroups Observations Reference
UK Increased risk Lakatos et al. (2010)
Decreased risk in males Maruszak et al. (2011)
No effect Maruszak et al. (2009) and Fachal et al. (2015)
K Defining SNP mt16224C decreased risk Maruszak et al. (2011)
Decreased risk in APOE4 carriers Carrieri et al. (2001) and Maruszak et al. (2011)
No effect Chinnery et al. (2000), van der Walt et al. (2005), Elson et al. (2006),
Fesahat et al. (2007), Mancuso et al. (2007) and Maruszak et al. (2009)
U Increased risk Fesahat et al. (2007)
Increased risk in males van der Walt et al. (2004)
Defining SNPs mt11467G, mt12308G, and mt12372A individually increased risk Lakatos et al. (2010)
Decreased risk in females van der Walt et al. (2004)
Decreased risk in APOE4 carriers Carrieri et al. (2001)
U5a1 decreases risk Maruszak et al. (2011)
No effect Chinnery et al. (2000), van der Walt et al. (2005), Elson et al. (2006),
Mancuso et al. (2007), Maruszak et al. (2009) and Fachal et al. (2015)
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TABLE 4 | Observed effects of mitochondrial superhaplogroup JT and haplogroups J and T on risk of AD.
Haplogroups Observations Reference
JT Decreased risk in females Maruszak et al. (2011)
No effect Maruszak et al. (2009) and Fachal et al. (2015)
J Decline in cognitive function comparing to H Tranah et al. (2012)
J2b defining SNP mt7476T, mt5633T, and mt15812A increased risk Chagnon et al. (1999)
No effect Chinnery et al. (2000), van der Walt et al. (2005),
Elson et al. (2006), Fesahat et al. (2007),
Mancuso et al. (2007), Maruszak et al. (2009) and Fachal et al. (2015)
T Increased risk for dementia comparing to H Tranah et al. (2012)
T defining SNP mt709A and mt15928A decreased risk Chagnon et al. (1999)
Decreased risk in females Maruszak et al. (2011)
No effect Chinnery et al. (2000), van der Walt et al. (2005),
Elson et al. (2006), Fesahat et al. (2007),
Mancuso et al. (2007), Maruszak et al. (2009) and Fachal et al. (2015)
in an African American population, haplogroup L1 was found
to have increased risk for developing dementia (Tranah et al.,
2014). In Asians, subhaplogroups G2a, B4c1 and N9b1 were
reported to be associated with AD in Japanese populations,
and haplogroup B5 was reported to be associated with AD
in Han Chinese (Takasaki, 2008, 2009; Bi et al., 2015; see
Table 5).
As reviewed here, the field has not reached consensus on the
effect of mitochondrial haplogroups on late onset AD (LOAD).
Different sets of haplogroups are identified in different studies
and different studies could identify opposite effects of the same
mitochondrial haplotype on risk of LOAD. Moreover, multiple
studies involving Caucasians of European descendant (European
descents in UK and US, Tuscans, Spanish and Old order Amish
from Indiana and Ohio) did not detect associations between
any haplogroup and AD (Chinnery et al., 2000; van der Walt
et al., 2005; Elson et al., 2006; Mancuso et al., 2007; Fachal
et al., 2015; see Tables 2–5). While the controversy may be
driven by differences in the distribution of subhaplogroups
within the studied population or different DNA sources (e.g.,
postmortem brain tissue vs. peripheral blood), the discrepancies
between studies also suggested that as intriguing as the results
are, mitochondrial genetic variances are unlikely to be the
sole driving force of LOAD. Further, the most consistent risk
factor for LOAD is APOE genotype, but it alone is not an
absolute determinant. Below, we determine the relationship
between mitochondrial haplogroup and APOE genotype on
risk of AD.
TABLE 5 | Association between some Asian mitochondrial haplogroups
and the risk of Alzheimer’s disease.
Haplogroups Observations References
L1 Increased risk Tranah et al. (2014)
G2a Increased risk Takasaki (2008, 2009)
B4c1 Increased risk Takasaki (2009)
N9b1 Increased risk Takasaki (2009)
B5 Increases risk Bi et al. (2015)
Studies listed in chronological order.
THE INTERACTION BETWEEN
MITOCHONDRIAL HAPLOGROUP AND
APOE GENOTYPE ON RISK OF AD
APOEε4 genotype is a widely recognized risk factor for AD,
and has been repeatedly confirmed in the studies reviewed
herein (Corder et al., 1993; Poirier et al., 1993; Rebeck et al.,
1993; Saunders et al., 1993; Carrieri et al., 2001; Edland
et al., 2002; Coto et al., 2011; Maruszak et al., 2011). Further,
APOEε4 has been associated with mitochondrial dysfunction
and glucose hypometabolism in brain (Reiman et al., 2001,
2004, 2005; Mosconi et al., 2004a,b,c, 2005, 2008; Valla
et al., 2010; Wolf et al., 2013). Compared to non-carriers,
APOEε4 carriers showed reduced cerebral parietal glucose
metabolism among cognitive normal elderlies with family history
of AD (Small et al., 1995, 2000). In APOEε4 positive MCI
patients, reduced regional cerebral metabolic rate of glucose
consumption (rCMRglc) was detected in temporoparietal and
posterior cingulate cortex (Mosconi et al., 2004b). In AD
patients, more severe hypometabolism was detected in the
parietal, temporal, and cingulate areas in APOEε4 carriers
than non-carriers (Mosconi et al., 2004c; Drzezga et al.,
2005). Brain glucose hypometabolism was also more widespread
in APOEε4 positive AD patients (Mosconi et al., 2004a).
On the therapeutic side, mild-to-moderate AD patients who
are APOEε4 carriers were shown to be less responsive to
rosiglitazone, which can improve mitochondrial efficiency
and glucose metabolism (Risner et al., 2006; Roses et al.,
2007).
In longitudinal studies, APOEε4 carriers had significantly
greater rCMRglc decline in the vicinity of temporal,
posterior cingulate, and prefrontal cortex, basal forebrain,
parahippocampal gyrus, and thalamus (Reiman et al., 2001;
Mosconi et al., 2008). Decrease of glucose metabolism
was also evident in young and middle-aged APOEε4
carriers in posterior cingulate, parietal, temporal, and
prefrontal cortex, as well as thalamus (Reiman et al., 2004;
Mosconi et al., 2008). The effect of APOEε4 allele has
also been shown to be gene dose dependent with APOEε4
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TABLE 6 | Three modes of interactions between APOEε4 status and
mitochondrial haplogroups in modulating the risk of AD.
Interactions Haplogroups/SNPs Reference
Neutralizing K Carrieri et al. (2001) and
Maruszak et al. (2011)
U Carrieri et al. (2001)
Enabling mt4336C (H) Edland et al. (2002)
Synergistic H5 Maruszak et al. (2011)
mt7028C (H) Coto et al. (2011)
Haplogroups K and U could neutralize the risk of APOEε4 on AD. Haplogroup
H defining SNP mt4336C was associated with LOAD in APOEε4 carriers
only. Subhaplogroup H5 and haplogroup H defining SNP mt7028C could act
synergistically with APOEε4 to increase the risk of LOAD.
homozygote carriers showing greater hypometabolic deficit
relative to APOEε3/4 heterozygote carriers (Reiman et al.,
2005).
At the cellular level, APOEε4 gene expression in human
was associated with down-regulation of genes involved
in mitochondrial oxidative phosphorylation and energy
metabolism (Xu et al., 2006, 2007). APOEε4 gene expression
was also found to be associated with lower mitochondrial
cytochrome oxidase activity in posterior cingulate cortex
among young adults with family history of AD (Valla et al.,
2010). Neurons from humanized APOEε4 knock-in mice
had significantly lower amount of all five electron transport
chain complexes comparing to those from APOEε3 knock-
in mice (Chen et al., 2011). Proteomic analysis revealed
decreased expression of proteins involved in the TCA
cycle, glucose, lipid and amino acid metabolism in APOEε4
knock-in mice (Shi et al., 2014). Further, cytochrome c
levels were significantly lower in ApoEε4 mice compared
with ApoEε3 mice (Shi et al., 2014). In vitro studies also
suggested that truncated APOEε4 fragment can interact directly
with mitochondria and cause mitochondrial dysfunction
and neurotoxicity (Chang et al., 2005; Mahley et al., 2007).
Given the association between decreased bioenergetic
capacity in brain and the risk of AD, an interaction
between APOE genotype and mitochondrial haplotypes is
possible.
After stratifying by APOEε4 status, three interesting modes
of interactions between APOEε4 status and mitochondrial
haplogroups in modulating the risk of AD were apparent (see
Table 6).
The first mode is a neutralizing effect of mitochondrial
haplogroup on the effect of APOEε4 on risk of AD (see
Table 6). Early studies identified a non-random association
between mitochondrial haplogroup and APOEε4 status in AD
patients (Carrieri et al., 2001). Specifically, while APOEε4 carriers
had significantly higher odds ratio for AD, those belonging to
haplogroups K and U did not, indicating a neutralizing effect of
haplogroups K and U on the risk of APOEε4 gene status (Carrieri
et al., 2001). The non-random distribution of mitochondrial
haplogroups associated with APOEε4 status and the neutralizing
effect of mitochondrial haplogroup K on APOEε4 were later
confirmed by Maruszak et al. (2011).
The second mode is an enabling effect of APOEε4 on
mitochondrial genetic variances as risk factors for AD (see
Table 6). In non-APOEε4 carriers, SNPmt4336C (a defining SNP
for subhaplogroup H5a) was not an AD risk factor, however, in
APOEε4 carriers, the same SNP was a risk factor for AD (Edland
et al., 2002). This study indicated that APOE genotype could
explain the earlier disparity regarding the association between
SNP mt4336C and AD (Shoffner et al., 1993; Hutchin and
Cortopassi, 1995; Wragg et al., 1995; Zsurka et al., 1998).
A synergistic effect was also observed between APOEε4
and mitochondrial haplotypes (see Table 6). For example, SNP
mt7028C, a defining SNP for haplogroup H, and subhaplogroup
H5 were suggested to act synergistically with APOEε4 to increase
risk for AD (Coto et al., 2011; Maruszak et al., 2011).
As with the association between mitochondrial haplotype and
the risk of late onset AD, the interaction between APOEε4 and
mitochondrial genetic variances in modulating the risk of late
onset AD remains debatable. Multiple studies failed to identify
any correlation between mitochondrial haplogroup and APOEε4
status or failed to identify an interaction between the two on the
risk of developing AD (Zsurka et al., 1998; Chinnery et al., 2000;
van der Walt et al., 2005; Mancuso et al., 2007; Lakatos et al.,
2010; Santoro et al., 2010; Ridge et al., 2013). Collectively, these
disparate findings on the association between mitochondrial
TABLE 7 | Sex differentiates effects of mitochondrial haplogroups on risk of AD.
Haplogroups/SNPs Female Male Authors
H Increased risk No effect Maruszak et al. (2009, 2011)
H5 Increased risk No effect Santoro et al. (2010)
HV Increased risk No effect Maruszak et al. (2009, 2011)
T Decreased risk No effect Maruszak et al. (2011)
JT Decreased risk No effect Maruszak et al. (2011)
U Decreased risk Increased risk van der Walt et al. (2004)
KU No effect Decreased risk Maruszak et al. (2011)
mt7028C (H) Increased risk No effect Maruszak et al. (2009)
mt13368A (T) Decreased risk No effect Maruszak et al. (2011)
mt13708G (non-J) No effect Increased risk Maruszak et al. (2009)
mt9055A (K) No effect Decreased risk Maruszak et al. (2011)
Haplogroups and SNPs identified to have sex differences from literatures are listed. A possible haplogroup defined by the SNPs listed is indicated in the parenthesis
following the SNP.
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haplotype, APOE genotype, and risk of AD emphasize the
importance of a precision medicine approach that considers
mitochondrial genetic variance in combination with nuclear
genetics.
MITOCHONDRIAL HAPLOGROUP AND
SEX DIFFERENCES AND RISK OF
ALZHEIMER’S DISEASE
Females are at greater lifetime risk for LOAD, and also have
higher prevalence and incidence rate than all age-matched males
(Brookmeyer et al., 1998; Mielke et al., 2014; Grimm et al.,
2016). The higher risk for female is also evident in faster disease
progression and greater burden of AD pathology (Aguero-
Torres et al., 1998; Corder et al., 2004; Barnes et al., 2005;
Skup et al., 2011; Kelly et al., 2013; Mielke et al., 2014; Grimm
et al., 2016). While the underlying mechanism remains to be
elucidated, increased mitochondrial oxidative stress may play a
role (Schuessel et al., 2004; Mandal et al., 2012). Given the effect
of mitochondrial genetic variances on mitochondrial function
and risk of AD, it is of interest to identify any interaction
between mitochondrial haplotypes and sex difference on risk of
LOAD.
While almost all the reviewed studies recognized sex
differences on risk of LOAD, only a few studied the effects
of mitochondrial genetic variances in each sex (van der Walt
et al., 2004; Maruszak et al., 2009, 2011; Santoro et al., 2010;
see Table 7). Within these studies, some mitochondrial genetic
variances were found to be associated with AD in females
only (van der Walt et al., 2004; Maruszak et al., 2009, 2011;
Santoro et al., 2010). Superhaplogroup JT, haplogroup T, a
haplogroup T defining SNP mt13368A, a haplogroup U defining
SNP 12308G and a non-H defining SNP mt7028T were found
to exert protective effects only in females (van der Walt et al.,
2004; Maruszak et al., 2011; see Table 7). Superhaplogroup
HV, haplogroup H, subhaplogroup H5 and a haplogroup H
defining SNP mt7028C were identified as risk factors for only
in females (Maruszak et al., 2009, 2011; Santoro et al., 2010; see
Table 7).
In contrast, some variances affected only males (see Table 7).
Superhaplogroup UK, and SNP mt9055A, a defining SNP
for haplogroup K, were found to be associated with reduced
risk of AD in males, while SNP mt13708G (for many non-J
haplogroups), and SNP mt10398A, a defining SNP for some
subhaplogroups of U, were associated with increased risk only
in males (van der Walt et al., 2004; Maruszak et al., 2009,
2011; see Table 7). Certain mitochondrial genetic variances
also showed opposite effects in each sex. For example,
haplogroup U was associated with increased risk in males
but decreased risk in females (van der Walt et al., 2004; see
Table 7).
FIGURE 3 | A conceptual framework where the combination of mitochondrial and nuclear genetic risk factors plus sex as a higher risk factor for
LOAD. Each of the three factors: sex, APOEε4 genotype and mitochondrial genetic variance has moderate risk for developing late onset AD, but constitutes a much
higher risk when combined.
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These results indicate that previously observed associations
between mitochondrial haplogroups and AD could be driven by
sex. Conversely, the effects observed in one sex could be diluted
in the whole population, or be neutralized by the other sex,
resulting in non-significant associations.
CONCLUSION AND PERSPECTIVES
Mounting evidence suggested a central role of mitochondrial
dysfunction in the etiology of late onset AD. As reviewed
above, disruption of mitochondrial bioenergetics, structure
and dynamics have all been indicated in AD patients. Given
the maternal pattern of inheritance of late onset AD and
mitochondrial genome, herein we reviewed the association of
mitochondrial genetic variances on bioenergetics, respiratory
phenotypes and risk of developing LOAD. While the outcomes
remain debatable, a large body of science supports an association
between mitochondrial genetic variances and differences in
bioenergetics and AD susceptibility. Several factors can help
explain the disagreement. First, although most studies were
conducted in descendants of European origin, the geographic
distribution of participants were drastically different, which
could result in diverse nuclear genetic background. Since
mitochondria communicate extensively with the nucleus,
uncontrolled nuclear background can potentially mask effects of
mitochondrial genetic variances. Second, as we have reviewed,
observations could be driven by certain subhaplogroups, thus
results obtained from different populations may be biased by
their dominant subhaplogroup. Third, given the heteroplasmic
nature of the mitochondrial DNA, accumulated mutations
throughout aging may be haplotype and tissue specific (Wallace,
2005), which could contribute to the discrepancies between
studies that had different sources of mtDNA (e.g., brain
tissues vs. peripheral blood samples; Wallace, 1994). And last,
the criteria for mitochondrial haplogroup assignment evolved
during the past two decades. Initial studies used haplotype
assignment based on only 10 SNPs in the control region,
whereas more recent studies used 138 SNPs across the whole
human mitochondrial genome. As a result, some ambiguous
assignments were resolved and more subhaplogroups were
identified.
The data also indicate that mitochondrial haplotype is one
factor among several that impacts risk of AD. This is
consistent with the multifactorial nature of aging trajectories
and risk for LOAD. A systems biology approach that integrates
mitochondrial genetic variances and risk factors such as
APOEε4 genotype and sex is a step towards resolving
disparities across studies of mitochondrial haplotype and risk
of neurodegenerative diseases associated with mitochondrial
dysfunction (see Figure 3). More importantly, we propose a
precision medicine approach, where nuclear genetic risk factors
(especially APOEε4 genotype), mitochondrial haplotypes, and
sex differences can be incorporated into future therapeutic
designs for LOAD.
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